HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

277

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Interventions

DRUG: Patritumab Deruxtecan (Fixed dose)
DRUG: Patritumab Deruxtecan (Up-Titration)

Sponsor

Daiichi Sankyo

Collaborators

[object Object]
[object Object]